The Indonesian Biomedical Journal
Cure8 research brief
Why This Matters
People with diabetes and fatty liver disease may eventually benefit from new adjunctive therapies that target liver inflammation, fibrosis, and oxidative stress; this study reports promising preclinical signals for a cell‑derived secretome combined with insulin.
Who Should Pay Attention
Researchers; clinicians treating metabolic liver disease and diabetes; scientists working on regenerative or cell‑free therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is an animal (rat) study published as an abstract in The Indonesian Biomedical Journal that tested whether combining insulin with the secretome (cell-free products) from umbilical-cord mesenchymal stem cells (UC‑MSCs) improves liver injury in a diabetic model of metabolic dysfunction‑associated steatotic liver disease (MASLD).
The researchers treated diabetic MASLD rats for four weeks with insulin, UC‑MSC secretome, both, or control medium, then measured blood chemistry, liver histology, IL‑6, and antioxidant enzyme (SOD) activity.
The combination group showed trends toward better glucose and lipid values, higher hepatic SOD and lower IL‑6 (not statistically significant), reduced hepatomegaly, improved steatosis, and a statistically significant reduction in fibrosis severity compared with untreated diabetic rats.
This is preclinical work in rodents testing a cell‑derived therapy as an adjunct to insulin; it is not clinical evidence for humans. The findings support further preclinical and early‑phase translational research rather than immediate clinical use.
Keep In Mind
Preclinical rat study reported in a journal abstract. Not evidence for human treatment; additional preclinical and clinical testing required.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationThe Indonesian Biomedical Journal
PublisherSecretariat of The Indonesian Biomedical Journal
AuthorsShirly Gunawan, Siufui Hendrawan, Olivia Marcelina +2 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 31, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Potential effect of ethanolic extract of Abutilon indicum (L.) against acetic acid induced ulcerative colitis in albino rats
This preclinical study suggests a traditional medicinal plant extract may reduce inflammation and tissue damage in an experimental model of ulcerative colitis, which could guide future drug-discovery research relevant to...
Pathological accumulation of aged neutrophils contributes to intestinal inflammation in inflammatory bowel disease.
If validated, the study points to a specific neutrophil subset that may drive inflammation and barrier damage in IBD, and to CXCR4 as a possible therapeutic target. That could open new biology-based treatment approaches...
A Comparative Study of Nintedanib versus Conventional Drugs in the Treatment of Inflammatory Bowel Disease-Associated Intestinal Fibrosis.
Intestinal fibrosis (stricture) is a serious, hard-to-treat complication of IBD/Crohn's disease. This preclinical study tests whether an antifibrotic drug used in lung fibrosis might reduce fibrosis in the gut, which...